Diffuse astrocytoma
MONDO:0016686A low-grade (WHO grade II) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.
Also known as: WHO grade II astrocytoma, astrocytoma, diffuse, astrocytoma, diffuse, malignant, diffuse astrocytoma, grade II astrocytic neoplasm, grade II astrocytic tumor, grade II astrocytic tumour, grade II astrocytoma
1476 clinical trials for this condition and its sub-types, 25 tagged with Diffuse astrocytoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Diffuse astrocytoma
-
Fibrillary astrocytoma 3 trials
-
Gemistocytic astrocytoma 0 trials
-
Protoplasmic astrocytoma 0 trials
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…
Phase 1/2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
AI-Powered radiation adjusts in real time to fight brain tumors
Disease control Recruiting nowThis study tests a new way to deliver radiation therapy for people with diffuse glioma, a type of brain tumor. Instead of giving the same dose throughout treatment, doctors will use MRI and PET scans taken during treatment to adjust the radiation dose to target resistant areas an…
Phase 2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New combo therapy targets aggressive brain tumors in phase 2 trial
Disease control Recruiting nowThis study tests a more intense treatment for a fast-growing type of brain cancer called IDH wildtype glioma. It combines higher doses of radiation with the chemotherapy drug temozolomide to try to stop the tumor from growing longer. The trial will enroll 40 adults with this spec…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Promising drug combo targets Hard-to-Treat brain cancers
Disease control Recruiting nowThis study tests two drugs—retifanlimab (an immunotherapy) and DFMO (a growth blocker)—alone or together in 33 adults with progressive high-grade glioma, an aggressive brain cancer. The goal is to find the safest, most effective dose and see if the combination boosts the immune s…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Radioactive drug targets brain tumors in early trial
Disease control Recruiting nowThis early-phase study tests a radioactive drug called 177Lu-PSMA-617 combined with standard chemotherapy (temozolomide) for people with aggressive IDH wild type gliomas. The goal is to see if the combination is safe and to get a first look at whether it helps control tumor growt…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New study tests if proton radiation can spare brain tissue without hurting survival
Disease control Recruiting nowThis study compares proton therapy to standard photon radiation for people with slow-growing brain tumors (IDH-mutated gliomas). The goal is to see if proton therapy, which targets tumors more precisely, can reduce side effects and maintain quality of life without shortening surv…
Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill shows promise in early brain tumor trial
Disease control Recruiting nowThis early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.
Phase 1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
AI-Designed vaccine takes on deadly brain cancer in first human trial
Disease control Recruiting nowThis early-phase trial tests a personalized vaccine called Tamavaq NeoVaccine in 29 adults with newly diagnosed glioma, a type of brain cancer. The vaccine is custom-made for each patient using AI and quantum mechanics to target unique cancer markers. The main goal is to check if…
Early phase 1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New trial tests if proton beam therapy spares brain function better than standard X-Rays
Disease control Recruiting nowThis phase 3 trial compares proton beam therapy to standard photon radiotherapy in 156 adults with primary brain tumors. The goal is to see if proton therapy, which delivers less radiation to healthy brain tissue, improves functional survival—meaning living longer without tumor r…
Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jun 26, 2026 18:34 UTC
-
New imaging test may help doctors spot real tumor growth in kids with brain cancer
Diagnosis Recruiting nowThis study tests whether a special PET scan called 18F-Fluciclovine can help doctors tell the difference between actual tumor growth and harmless changes caused by treatment in children with high-grade glioma. About 30 children aged 1 to 21 will receive the scan after radiation t…
Early phase 1 • Sponsor: Children's Hospital of Philadelphia • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
New study probes brain tumor metabolism with drug combo
Knowledge-focused Recruiting nowThis early phase trial at Mayo Clinic is studying how two drugs, DFMO and AMXT 1501, change the metabolism of brain tumors (gliomas) in 18 adult patients. The goal is to measure molecules in the tumor's fluid to understand how these drugs affect tumor growth and survival. Partici…
Early phase 1 • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC